An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis

Vaccine

Volumn 27, Issue 48, 2009, Pages 6712-6722

  Wang, Qi long ^a   Pan, Qin ^a   Ma, Yunfeng ^a   Wang, Kun ^a   Sun, Ping ^a   Liu, Shengwu ^a   Zhang, Xiao Lian ^a  

^a School of Pharmaceutical Sciences   (China)

Author keywords

Mucosal immunity; Mycobacterium tuberculosis vaccine; Salmonella vector

Indexed keywords

BACTERIAL VACCINE; BACTERIAL VECTOR; BCG VACCINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GRANZYME B; HYBRID PROTEIN; PLASMID DNA; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME SYNTHESIS; FEMALE; HUMORAL IMMUNITY; IMMUNITY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TUBERCULOSIS;

ACYLTRANSFERASES; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANZYMES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 70350570502     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.096     Document Type: Article

References (42)

1. Dye C., Scheele S., Dolin P., Pathania V., and Raviglione M.C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 (1999) 677-686
2. Shah N.S., Pratt R., Armstrong L., Robison V., Castro K.G., and Cegielski J.P. Extensively drug-resistant tuberculosis in the United States 1993-2007. JAMA 300 (2008) 2153-2160
3. Golub J.E., Durovni B., King B.S., Cavalacante S.C., Pacheco A.G., Moulton L.H., et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro Brazil. AIDS 22 (2008) 2527-2533
4. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
5. Franco-Paredes C., Rouphael N., del R.C., and Santos-Preciado J.I. Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates. Int J Infec Dis 10 (2006) 93-102
6. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 (1999) 1520-1523
7. Brandt L., Oettinger T., Holm A., Andersen A.B., and Andersen P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157 (1996) 3527-3533
8. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9 (2003) 533-539
9. Mattow J., Schaible U.E., Schmidt F., Hagens K., Siejak F., Brestrich G., et al. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 24 (2003) 3405-3420
10. Wu-Hsieh B.A., Chen C.K., Chang J.H., Lai S.Y., Wu C.H., Cheng W.C., et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 33 (2001) 1336-1340
11. Shi C., Wang X., Zhang H., Xu Z., Li Y., and Yuan L. Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette-Guérin. Acta Biochim Biophys Sin (Shanghai) 39 (2007) 290-296
12. Xu Y., Wang B., Chen J., Wang Q., Zhu B., Shen H., et al. Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of Mycobacterium tuberculosis. Scand J Immunol 64 (2006) 476-481
13. Derrick S.C., Yang A.L., and Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 23 (2004) 780-788
14. Weinrich Olsen A., van Pinxteren L.A., Meng O.L., Birk R.P., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 (2001) 2773-2778
15. Gahan M.E., Webster D.E., Wijburg O.L., Wesselingh S.L., and Strugnell R.A. Impact of prior immunological exposure on vaccine delivery by Salmonella enterica serovar Typhimurium. Vaccine 26 (2008) 6212-6220
16. Kotton C.N., and Hohmann E.L. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun 72 (2004) 5535-5547
17. Roland K.L., Tinge S.A., Killeen K.P., and Kochi S.K. Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther 7 (2005) 62-72
18. Boyle E.C., Bishop J.L., Grassl G.A., and Finlay B.B. Salmonella: from pathogenesis to therapeutics. J Bacteriol 189 (2007) 1489-1495
19. Hoiseth S.K., and Stocker B.A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291 (1981) 238-239
20. Li Y., Wang S., Xin W., Scarpellini G., Shi Z., Gunn B., et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun 76 (2008) 5238-5246
21. Feng Y., Wang S.Q., Luo F.L., Ruan Y., Kang L., Xiang X.H., et al. A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice. Antiviral Res 80 (2008) 272-279
22. Parida S.K., Huygen K., Ryffel B., and Chakraborty T. Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model. Ann NY Acad Sci 1056 (2005) 366-378
23. Chen F., Zhou J., Luo F.L., Mohammed A.B., and Zhang X.L. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Biophys Res Commun 357 (2007) 743-748
24. Liao X.L., Ren H., Zhao P., Zhu S.Y., Cao J., Chen Z.H., et al. Efficient induction of mouse immune responses to hepatitis C virus by viral core protein-carrying attenuated Salmonella typhimurium. Viral Immunol 20 (2007) 469-478
25. Li P.F., Wan Q., Feng Y., Liu M., Wu J.G., Chen X.W., et al. Engineering of N-glycosylation of Hepatitis C Virus Envelope Protein E2 Enhances T cell responses for DNA immunization. Vaccine 25 (2007) 1544-1551
26. Lefrancois L., and Marzo A.L. The descent of memory T-cell subsets. Nat Rev Immunol 6 (2006) 618-623
27. Esser M.T., Marchese R.D., Kierstead L.S., Tussey L.G., Wang F., Chirmule N., et al. Memory T cells and vaccines. Vaccine 21 (2003) 419-430
28. Accapezzato D., Francavilla V., Paroli M., Casciaro M., Chircu L.V., Cividini A., et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 113 (2004) 963-972
29. Hong M.S., Dan J.M., Choi J.Y., and Kang I. Age-associated changes in the frequency of naïve, memory and effector CD8+ T cells. Mech Ageing Dev 125 (2004) 615-618
30. + T cells at the site of infection in human chronic pulmonary tuberculosis. Infect Immun 75 (2007) 5210-5222
31. Toossi Z., Mayanja-Kizza H., Kanost A., Edmonds K., McHugh M., and Hirsch C. Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by Mycobacterium tuberculosis and during human tuberculosis. Scand J Immunol 60 (2004) 299-306
32. + T cells in tuberculosis. Am J Respir Crit Care Med 166 (2002) 1116-1121
33. Weichold F.F., Mueller S., Kortsik C., Hitzler W.E., Wulf M.J., Hone D.M., et al. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun 8 (2007) 334-343
34. Caruso A.M., Serbina N., Klein E., Triebold K., Bloom B.R., and Flynn J.L. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 162 (1999) 5407-5416
35. Mogues T., Goodrich M.E., Ryan L., LaCourse R., and North R.J. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 193 (2001) 271-280
36. Winslow G.M., Cooper A., Reiley W., Chatterjee M., and Woodland D.L. Early T-cell responses in tuberculosis immunity. Immunol Rev 225 (2008) 284-299
37. Luo F.L., Feng Y., Liu M., Li P.F., Pan Q., Jeza V.T., et al. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol 14 (2007) 990-997
38. Mollenkopf H.J., Groine-Triebkorn D., Andersen P., Hess J., and Kaufmann S.H. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine 19 (2001) 4028-4035
39. Hess J., Grode L., Hellwig J., Conradt P., Gentschev I., Goebel W., et al. Protection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa antigen of Mycobacterium bovis BCG. FEMS Immunol Med Microbiol 27 (2000) 283-289
40. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 89 (1992) 12013-12017
41. Liu C., Fan M., Bian Z., Chen Z., and Li Y. Effects of targeted fusion anti-caries DNA vaccine pGJA-P/VAX in rats with caries. Vaccine 26 (2008) 6685-6689
42. Kim S.J., Lee C., Lee S.Y., Kim I., Park J.S., Sasagawa T., et al. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Ther 10 (2003) 1268-1273